COVID-19: How Safe is Bharat Biotech's Covaxin for Vaccinating Children?

The Subject Expert Committee has recommended to the DCGI to grant emergency use authorisation for Covaxin for

In big news for India’s vaccination drive, the Subject Expert Committee (SEC) has recommended to the Drug Controller General of India (DCGI) to grant emergency use authorisation for Bharat Biotech’s Covaxin for children as young as two years.

On 12 October, the expert panel in a statement said that “after detailed deliberation, the committee recommended for grant of market authorisation of the vaccine for the age group of 2 to 17 years for restricted use in an emergency.”